AEON Biopharma (AEON) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AEON Biopharma (AEON) has outperformed TScan Therapeutics (TCRX) over the past year, losing 66.3% versus a loss of 88.5%. TScan Therapeutics is the larger company by market cap ($15.5 million vs $15.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEON | TCRX |
|---|---|---|
| Share price | $0.31 | $0.2282 |
| Market cap | $15.46M | $15.47M |
| 1-day change | -0.40% | -17.59% |
| YTD return | -71.82% | -77.18% |
| 1-year return | -66.30% | -88.47% |
| 5-year return | — | -96.62% |
| EPS (TTM) | $-4.39 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.45 | $2.57 |
| 52-week low | $0.177 | $0.224 |
| Distance from 52-week high | -78.62% | -91.12% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +487.10% | +338.21% |
| Average volume | 8.59M | 783.59K |
| Shares outstanding | 49.88M | 63.50M |
| Employees | 8 | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AEON has outperformed TCRX by 22.2 percentage points over the past year.
About AEON Biopharma
AEON stock →AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
AEON vs TCRX FAQ
Which is bigger, AEON Biopharma or TScan Therapeutics?
TScan Therapeutics (TCRX) is larger, with a market capitalization of $15.47M compared with $15.46M for AEON Biopharma (AEON).
Which stock has performed better over the past year, AEON or TCRX?
AEON returned -66.30% over the past 12 months, compared with -88.47% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are AEON Biopharma and TScan Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for AEON Biopharma and Biotechnology: Biological Products (No Diagnostic Substances) for TScan Therapeutics.